Simulations Plus to Deploy AI-Enabled GastroPlus, MonolixSuite in Pharma Collaborations
Simulations Plus has launched strategic collaboration programs with three major pharmaceutical companies to integrate its AI-enabled modeling platforms—GastroPlus, MonolixSuite, ADMET Predictor and Thales—into real-world drug development workflows. These partnerships will establish governance standards and provide scientific feedback to refine platform capabilities, supporting enterprise-scale adoption and driving future commercial models.
1. Strategic Collaboration Programs Launched
Simulations Plus announced strategic collaboration programs with three major pharmaceutical companies to embed AI-enabled modeling across the drug development lifecycle, signaling a shift from experimentation to practical implementation of its platforms.
2. AI-Driven Workflow Integration
The programs leverage Simulations Plus’ core platforms—GastroPlus, MonolixSuite, ADMET Predictor and Thales—to enable natural language interaction, automated data processing, coordination of multi-engine simulations, and generation of interpretable outputs from complex pipelines.
3. Enterprise Adoption and Governance Standards
Partners will work directly with Simulations Plus and their IT teams to define deployment, governance and integration standards, focusing on transparency, reproducibility and traceability as AI becomes embedded in existing systems.
4. Impact on Product Development Roadmap
Real-time scientific feedback from these collaborations will inform future platform evolution and commercial models, accelerating the translation of AI-driven efficiencies into reproducible outcomes at enterprise scale.